Actively Recruiting
Ultrasensitive SERS Chip Technology to Improve Early Screening and Diagnosis of Epithelial Ovarian Cancer in Women Aged 18 to 70
Led by Anhui Provincial Hospital · Updated on 2024-10-15
70
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating a new high-sensitivity and high-specificity SERS chip created with femtosecond laser technology to help screen and diagnose epithelial ovarian cancer earlier. This open, single-center, prospective study aims to analyze blood samples from ovarian cancer patients and healthy controls to identify cancer-specific signals. The study will develop a statistical algorithm model to improve early detection and intervention for ovarian cancer patients. The study involves collecting blood samples from two groups ovarian cancer patients with various types of the disease and normal control subjects undergoing surgery for benign conditions. Researchers will analyze the Raman spectra of biomolecules from these samples using the SERS chip to identify unique cancer signals. The study does not involve any treatment intervention but focuses on building a database of characteristic Raman information and developing classification methods for early diagnosis. Participants will provide blood samples for analysis and have their clinical data reviewed. The study will measure progression-free survival at one year and overall survival at three years as primary outcomes. Participants must consent to sample collection and have good organ function. The study includes participants aged 18 to 70 years, with ongoing monitoring and data collection until the study ends in 2030.
CONDITIONS
Brief Title
Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer
Research Team
Y
Ying Zhou, MD
Y
Ying Zhou, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here